Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Semin Pediatr Neurol. Author manuscript; available in PMC 2016 July 13.
Published in final edited form as:
PMCID: PMC4943027

Current Therapeutic Options in Sturge-Weber Syndrome

Anne Comi, MD*


Sturge-Weber syndrome is a vascular malformation syndrome consisting of a facial port-wine birthmark associated with malformed leptomeningeal blood vessels and a choroid “angioma” of the eye. It is a rare neurocutaneous disorder that occurs sporadically, is not inherited, and is caused by a somatic mosaic mutation in GNAQ. In patients with Sturge-Weber syndrome, brain involvement typically presents in infancy with seizures, strokes, and stroke-like episodes, and a range of neurologic impairments. Standard treatment includes laser therapy for the birthmark, control of glaucoma through eyedrops or surgery, and the use of anticonvulsants. Increasingly low-dose aspirin is offered. Treatment with propranolol has been tried generally without the dramatic results seen in hemangiomas. Treatment with an anticonvulsant or low-dose aspirin or both before the onset of seizures is an option. Surgical resection may be offered to those whose seizures are medically refractory. Endocrine, medical rehabilitation and cognitive comorbidities are important to manage. In the future, new therapeutic options are likely to be offered stemming from preclinical studies and small pilot clinical trials currently ongoing. Discovery of the causative somatic mosaic mutation suggests new insights into the pathophysiology of this vascular malformation disorder, and potential novel treatment strategies for future study. The mutation results in constitutive overactivation of the Ras-Raf-MEK-ERK and the HIPPO-YAP pathways and inhibitors of these pathways may in the future prove useful in the treatment of Sturge-Weber syndrome.


Sturge-Weber syndrome is a vascular malformation involving the brain, skin, and eye. In Sturge-Weber syndrome a facial port-wine birthmark (PWB), a capillary malformation (Fig. 1), is associated with abnormal blood vessels in the brain leptomeningeal “angioma” (Fig. 2) and the eye (choroid “angioma”). The vascular malformation in the brain results in epilepsy and neurologic impairments such as intellectual disability, hemiparesis, visual impairments, and severe migraines. Eye involvement with the vascular malformation produces glaucoma and can lead to vision loss. Sturge-Weber syndrome is a condition with a spectrum of clinical manifestations, which can range from isolated brain involvement (in approximately 10% of the cases), isolated eye involvement, eye and skin or eye and brain involvement, to birthmark associated with both brain and skin involvement.

Figure 1
Child with Sturge-Weber syndrome, right-sided facial port-wine birthmark and right eye involvement. (Color version of figure is available online.)
Figure 2
Sturge-Weber syndrome brain involvement. (A) T1-weighted postcontrast enhanced axial MRI 3-T demonstrating increased leptomeningeal enhancement of the leftparietal-occipitallobes (arrow). Enhancement (arrow) in the left hemisphere also seen on coronal ...

The isolated birthmark is not usually referred to as Sturge-Weber syndrome, but rather it is generally called a facial PWB. Usually Sturge-Weber syndrome brain involvement is most frequently required to make the diagnosis; however the small subset of patients with the birthmark and eye involvement may sometimes be considered to have Sturge-Weber syndrome. If children with a facial PWB are older than 1 year and their contrast-enhanced magnetic resonance imaging (MRI) is normal, then they are very unlikely to have Sturge-Weber syndrome brain involvement.

A child, boy or girl, born with a PWB on the forehead or the upper eyelid, has a 10%–35% risk of brain involvement. When the PWB involves both the upper and the lower eyelid, the risk of glaucoma is approximately 50%.1 No population-based studies have been done; the estimates of prevalence range between 1 in 2000 and 1 in 50,000 live births. Isolated PWBs are very common; approximately 1 in 300 infants are born with it, most often located on the face, head, and neck.2 The somatic mosaic mutation causing Sturge-Weber syndrome is an activating mutation in GNAQ.3 Unexpectedly, the same R183Q mutation in GNAQ underlies a form of uveal melanoma.4 It has been hypothesized that the mutation occurring at a different time in development accounts for its resulting in a vascular malformation rather than a cancer. Furthermore, the timing of the mutation during fetal development probably determines the extent of Sturge-Weber syndrome involvement.5 The role of this GNAQ mutation is beginning to be understood, partly from extrapolation of data from the cancer literature.

In this article, we review the presentation, diagnosis, pathophysiology, and current treatment of Sturge-Weber syndrome, with a focus on therapeutic options both conventional and more controversial.6 The available treatment literature reviewed is primarily clinical cohort series; there are results from a few anonymous surveys. There have not been any randomized, placebo-controlled drug trials yet for Sturge-Weber syndrome. Although a couple of prospective open-label studies are currently ongoing, published drug studies to date are limited to retrospective open-label trials.


The PWB is present at birth and may initially be confused with a bruise. However, the “bruise” does not resolve and should be evaluated by a dermatologist or other vascular specialists so that it can be appropriately identified. The presence of a facial PWB should result in referral for treatment of the birthmark, as well as consultation with a neurologist and ophthalmologist for appropriate evaluation and treatment of brain or eye (or both) involvement, if necessary.

The diagnosis of Sturge-Weber syndrome brain involvement requires a contrast-enhanced MRI (Fig. 2). Susceptibility-weighted imaging and postcontrast flair sequences may increase the sensitivity. Contrast-enhanced MRI has decreased sensitivity in young infants and therefore neuroimaging must be repeated after a year of age.7,8 The diagnosis of Sturge-Weber syndrome brain involvement is made by visualizing the enhancing leptomeningeal vessels. Noncontrast susceptibility-weighted imaging (or blood oxygenation level dependent magnetic resonance venography) may be helpful in visualizing deep transmedullary veins. A recommended approach is to evaluate newborns with a history, an examination, and an electroencephalogram (EEG), and do an early MRI only if an abnormality is noted. Also, imaging newborns with a large facial PWB and an increased risk of brain involvement is a reasonable approach.

Infants with Sturge-Weber syndrome brain involvement usually present with seizures; approximately 75% of patients do so by 1 year of age and 90% within the first 2 years of life.9 A subset of patients develop early handedness or a visual gaze preference before onset of their seizures. Most often, however, infants acutely develop hemiparesis and focal deficits with the onset of their seizures, which are usually, but not always, focal and complex partial in nature. Neurologic, cognitive, and seizure control outcomes correlate with the extent of brain involvement and the age of seizure onset.10

Eye involvement in infancy presents with increased vascularity of the conjunctiva, buphthalmos (eye enlargement), or increased tearing.11 A child with a PWB of both the upper and the lower eyelid is at high risk of glaucoma. Screening for glaucoma every few months in infancy and early childhood is required to detect glaucoma and initiate treatment.12 Annual ophthalmologic examinations for life are recommended even if early evaluations do not detect glaucoma or evidence of eye involvement.

At this time the role for GNAQ testing in diagnosis remains to be established. It has been shown that the gene mutation is rarely, if ever, present in the blood of affected individuals. Skin or other abnormal tissue is required for testing. Therefore, development of a prenatal test is not a straightforward task. Furthermore, testing skin tissue would not distinguish an infant with an isolated birthmark from the one who has brain or eye involvement; the same mutation is found in both the syndrome and the isolated birthmark. There are a few other capillary malformations with phenotypic overlap that are sometimes confused with Sturge-Weber syndrome (ie, capillary malformation-macrocephaly syndrome). In these cases, testing may be helpful, especially in the future if gene-targeted therapy is available.


GNAQ codes for Gαq, an alpha subunit of a heterotrimeric guanosine-5′-triphosphate-binding protein coupled to Gβ and Gγ subunits and known to couple with several GCPRs (including certain serotonin and glutamate receptors, and endothelin-1, angiotensin 2 receptor type I, alpha-1 adrenergic receptors, and vasopressin type 1 and type B) which are important to vascular development and function. The mutation is predicted to decrease efficiency of the autohydrolysis and results in constitutive overactivation of downstream pathways.

In Sturge-Weber syndrome, histologic studies have reported an increased number of leptomeningeal vessels,13 and atrophy and calcification of the cortex particularly around blood vessels.14 Numbers of cortical vessels are decreased, however, as the brain atrophy develops over time with gliosis and neuronal loss; most likely this is secondary to tissue loss. Calcification, neuronal loss, and gliosis are secondary to brain injury from venous stasis and impaired brain perfusion. Several of the G protein-coupled receptors linked to Gαq are critical to blood vessel development and function, and their abnormal signaling may result in the vascular malformations.15 Cortical dysgenesis has been reported in surgical brain samples and suggests that Sturge-Weber syndrome brain involvement can include dysgenesis of cortical development, like focal cortical dysplasia (FCD) type IIa near the region of leptomeningeal angiomatosis, cortical dysplasia, and polymicrogyria.1416 It is possible that the somatic mutation affects the developing cortex itself, although available data to date suggest that cortical dysgenesis probably results either from impaired perfusion during brain development or because of the abnormal vascular development having indirect effects on cortical development ongoing at the same time.

PWBs and the abnormal Sturge-Weber blood vessels of the brain have demonstrated abnormal vascular innervation,1721 malformed cortical vessels lacking the normal cholinergic and sensory fibers.19 The vasoactive responses to temperature changes or seizures are also abnormal. Ictal spect (blood flow studies) in patients with Sturge-Weber syndrome have shown that during a seizure, blood flow can decrease to ischemic levels.2224 The normal response to a seizure is for blood flow to increase but this may not occur in Sturge-Weber syndrome and a stroke may result. Perfusion imaging has demonstrated impaired venous drainage resulting in impaired blood flow to affected brain regions, and abnormal automatic regulation of blood flow during seizures in patients with Sturge-Weber syndrome probably contributes to their stroke-like episodes. It is possible that the somatic mutation directly affects vascular innervation.

Research has also shown evidence of ongoing vascular remodeling,25 probably in response to chronic ischemia. Subjects with Sturge-Weber syndrome are more likely to have vascular factors, such as MMPs, in their urine than normal controls.26 Immunohistochemistry in Sturge-Weber syndrome tissue has demonstrated increased VEGF expression in cortical neurons and glia underlying the abnormal leptomeningeal vessels. Also, increased VEGFR-1, VEGFR-2, HIF-1α, and HIF-2α expressions in endothelial cells of the abnormal leptomeningeal vessels have been seen, suggesting that chronic tissue hypoxia and VEGF may drive ongoing vascular remodeling.25 The Ras-Raf-MEK-ERK-mTOR pathway can increase both VEGF27 and HIF activities,28 and the somatic mutation in GNAQ may also contribute to the vascular remodeling.

Di Trapani et al29 hypothesized that a putative vascular factor secreted by the vessel connective tissue contributed to the formation of the calcifications. This putative “vascular factor” may be the constitutive hyperactivation of GPCR-Gαq-ERK-mTOR pathways. Further study is required to identify additional important factors in this cascade and others affected by the R183Q mutation in GNAQ.

Current Treatment Options

The PWB is treated with laser procedures beginning in infancy when the flat, pink birthmark responds best and the birthmark is smaller.30 Early laser treatment may lessen later progression of the birthmark, which can consist of tissue hypertrophy, blebs, and complications affecting vision, airway, and swallowing. A variety of lasers have been developed over the years and are used, depending on color of the skin and color, thickness, and size of the birthmark; the lasers heat the hemoglobin within the blood vessels and destroy them, sparing surrounding skin structures. A series of laser treatments are required until no further lightening of the birthmark is seen. The treatments are painful and another controversial aspect of care is whether to do the laser treatments with sedation or anesthesia or with just a topical numbing agent. The trend seems to be moving away from putting infants to sleep for this as it may be done as often as monthly; however, there are a range of practices seen and little data to support an approach over any other. The PWB frequently recurs over time, requiring maintenance treatments.

Glaucoma (increased eye pressure) threatens vision as it can cause ischemic injury to the optical nerve. The increased intraocular pressure is treated with eyedrops, such as timolol and lantaprost, which decrease fluid production in the eye.31 The glaucoma can be difficult to control even with combinations of ophthalmic medications. When medical management is unsuccessful, various surgical approaches have been tried to drain fluid from the eye and relieve the excessive pressure. All too frequently, medical management fails or the glaucoma is fulminant (particularly in infants) and surgery is required with shunt placement or other means of relieving ophthalmic pressure.32 Theoretically, low-dose aspirin may relieve glaucoma due in part to venous hypertension; however, this requires further study. The major complication of surgical intervention for Sturge-Weber syndrome-related glaucoma stems from the risks of relieving the eye pressure too quickly; this can result in retinal hemorrhage and further sudden vision loss. There have been recent anecdotal reports using beta-blockers for Sturge-Weber syndrome; the results have been mixed and so do not appear to be generally successful. Antiangiogeneic ophthalmic treatments have also been anecdotally reported; however, this treatment needs to be more extensively studied. Laser therapy around the eye does not appear to adversely affect eye pressure.

The mainstay of neurologic treatment is the use of anticonvulsants to reduce seizures.

Epilepsy in Sturge-Weber syndrome can be difficult to control, occurring in clusters of seizures and episodes of status epilepticus.33 Although generalized seizures are seen, most seizures in patients with Sturge-Weber syndrome are focal motor with or without impaired consciousness. The most commonly used anticonvulsants in infants include oxcarbazepine, leviteracitam, and phenobarbital. A few patients develop infantile spams, which may respond to steroids, topiramate, vigabatrin, or ketogenic diet.34 Another small percentage of patients, taking anticonvulsants such as oxcarbazepine, carbamazepine, or lamotrigine, develop a generalized spike and wave pattern on EEG associated with myoclonic seizures35; these patients are usually switched from these anticonvulsants to others that cover both focal and generalized seizures, such as valproate, leviteracitam, or topiramate. Most patients attain reasonable seizure control on 1 or 2 anticonvulsants plus low-dose aspirin.36 Prolonged seizures, particularly in infants and young children, can result in stroke,23 and therefore aggressive antiepileptic management is warranted. Other patients, however, do not get a reasonable seizure control or develop intolerable side effects from medications. Many of them, with medically refractory seizures, also have a significant hemiparesis and visual-field cut, as well as intellectual impairments. In these situations, hemispherectomy or other surgical interventions are usually considered.

Low-dose aspirin (3–5 mg/kg/day) is also a therapeutic consideration although not all groups use it. There is published evidence that it decreases the frequency and severity of stroke-like episodes and seizures.3740 Side effects include increased bruising, nosebleeds, and gum bleeds; rarely allergic reactions and more seriously bleeding can occur. Lance et al36 reported the clinical experience over the past decade in 60 children with Sturge-Weber syndrome, and showed that low-dose aspirin was safely given to infants as young as 1 month of age. Subdural and subgaleal hematomas are rarely reported both on and off low-dose aspirin.41,42

As infants are increasingly being diagnosed before the onset of seizures, an important therapeutic question is what could be done to delay seizure onset and improve long-term neurologic and cognitive outcome. Those diagnosed with Sturge-Weber brain involvement presymptomatically can be offered treatment with anticonvulsants or low-dose aspirin or both. However, data demonstrating clear benefit of presymptomatic treatment are lacking. A study reported that phenobarbital was administered presymptomatically in infants with Sturge-Weber syndrome and a trend noted for improved cognitive outcome. However, the study groups were not randomized and the infants given presymptomatic phenobarbital had less brain involvement compared with those not presymptomatically treated; therefore the trend for their better outcome could relate to their less severe brain involvement.43 Infants with extensive bilateral brain involvement should perhaps be offered presymptomatic treatment with both an anticonvulsant and low-dose aspirin as they are at the highest risk for poor outcome and ischemic global cerebral injury, and they are not good surgical candidates.

However, for those patients whose seizures are refractory to medical management with anticonvulsants, additional treatment options include hemispherectomy or hemispherotomy, focal resection, the ketogenic or the Atkins diet,44 and the vagal nerve stimulator. For unilaterally involved patients, surgery should be considered for those who have failed 2 or more anticonvulsants combined with low-dose aspirin.45,46 The decision to proceed with surgery is easier in those patients who, in addition to the impairment and medically refractory seizures, also have hemiparesis and a significant visual-field deficit. Surgery should also be seriously considered in patients whose cognitive development is progressively falling behind normal, even if their seizures and other neurologic symptoms are not very severe. The most common scenario where surgery is pursued, in my experience, is children with frequent seizures or clusters of severe seizures, a significant hemiparesis, and visual-field deficits. For them, the need for surgery is obvious and the risk-benefit ratio greatly supports having the surgery.

Experience supports the conclusion that seizure control results in the best chance of optimal cognitive and neurologic development whether medically or surgically managed. When medical management fails, surgery should be considered especially when hemiparesis and visual deficits are already present. A couple of published series of approximately 20 patients with Sturge-Weber syndrome demonstrate that hemispherectomy is very successful (approximately 90% effective) in eliminating seizures in most cases. Focal resections is significantly less effective.46 The extensively bilaterally affected children with Sturge-Weber syndrome and severe brain involvement have the highest risk of very poor neurologic and cognitive outcome. Essentially most of their cortex is at risk for ischemic brain injury, atrophy, and calcification. For these infants, very aggressive treatment with anticonvulsants and low-dose aspirin is warranted. They are generally not considered good surgical candidates; hemispherectomy has been recommended only in bilaterally affected children with very severe disabling seizures primarily coming from 1 hemisphere and the surgery is considered palliative rather than potentially curative.47

In patients with Sturge-Weber syndrome, headaches, and particularly migraines, commonly begin at a young age, can worsen over time, and are frequently associated with their seizures. Sleep deprivation is a common trigger. Anticonvulsants that also prevent migraines, such as topiramate or valproate, can be helpful. Triptan medications have been safely used and are helpful for some patients,48 but most require a prophylactic agent.

Strokes and stroke-like episodes are common, particularly in infants and toddlers, and often associated with seizures or migraines or both. Stroke-like episodes can be defined as a focal neurologic deficit lasting longer than 24 hours; these impairments resolve over a period of days to weeks. Neurologic impairment that does not fully resolve but persists may be referred to as a stroke. Many children gradually acquire a hemiparesis in a stepwise fashion such that stroke events are not recognized; other children have clear acute onset of focal neurologic deficit. During a stroke-like episode the EEG often demonstrates focal slowing. Single-photon emission computed tomography studies show perfusion deficits.21 High apparent diffusion coefficient values are seen on MRI, and decreased N-acetylaspartate and choline peaks are found on proton magnetic resonance spectroscopy.49 Patients who are seizure free for a year or more demonstrate recovery of glucose hypometabolism and neurologic improvement.50

Endocrine abnormalities in Sturge-Weber syndrome require screening and treatment if present. These patients have an increased risk of hypothyroidism (commonly central) and growth hormone (GH) deficiency.51,52 GH deficiency is suspected when young childrens’ growth rate decreases and they are not following the percentile predicted by midparental height and bone age. In this case a serum insulin-like growth factor-1 level test should be performed to screen for GH deficiency, and if it is low then formal GH testing should be done. Central hypothyroidism or primary hypothyroidism also occurs with greater frequency in these patients than in the general population,52,53 usually associated with anticonvulsants’ use. Patients with symptoms such as excessive weight gain, dry skin, sleepiness, and constipation should have free T4 by equilibrium dialysis tested. If hypothyroidism is confirmed, treatment with synthroid relieves their symptoms.

Future Treatment Options

Research efforts for the future would increasingly be centered around targeted therapies. This is already being seen to some extent in the Phase I-II treatment trials studying the use of mechanistic target of rapamycin inhibitors for the treatment of PWB,54 and of medically refractory seizures in Sturge-Weber syndrome ( Another ongoing Phase I-II clinical trial of cannabidiol may in part target Gαq hyperactivation (

The current goal is to develop new treatments, which both ameliorate or reverse the symptoms of those patients already affected by the disease, and to prevent the symptoms of those who have yet to manifest clinical course progression. To achieve this goal the following efforts are needed: (1) to continue to create safe screening methods to detect presymptomatic brain and eye involvement, (2) to develop genetic in vitro and animal models of Sturge-Weber syndrome for screening of novel drug treatments, and (3) to perform new Phase I-II clinical trials to study the safety and possible efficacy of the new treatment strategies based on our growing understanding of the pathophysiology.

MEK and ERK inhibitors are now of interest and under discussion and inhibitors of the HIPPO-YAP pathway have also been proposed (Fig. 3). Safe use of these compounds is an important goal. It is expected that, within the next few years, patients would have the opportunity to participate in additional clinical drug trials as preclinical studies and screening programs bring forward additional targets and lead compounds for the treatment of Sturge-Weber syndrome.

Figure 3
Potential Treatment by inhibition of constitutive activation of Hippo-YAP and Ras-Raf-MEK-ERK-mTOR pathway: somatic mutation in GNAQ results in impaired autohydrolysis of Gαq with constitutive overactivation of downstream pathways, including increased ...


The author acknowledges funding from the National Institute of Neurological Disorders and Stroke (NINDS), United States, National Institutes of Health, United States, (NIH; U54NS065705), and from Celebrate Hope Foundation. The Brain Vascular Malformation Consortium (U54NS065705) is part of Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS. This consortium is funded through collaboration between NCATS and the NINDS.


1. Enjolras O, Riche MC, Merland JJ. Facial port-wine stains and Sturge-Weber syndrome. Pediatrics. 1985;76:48–51. [PubMed]
2. Powell J. Update on hemangiomas and vascular malformations. Curr Opin Pediatr. 1999;11:457–463. [PubMed]
3. Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368:1971–1979. [PMC free article] [PubMed]
4. Harbour JW. The genetics of uveal melanoma. An emerging framework for targeted therapy. Pigment Cell Melanoma Res. 2012;25:171–181. [PMC free article] [PubMed]
5. Poduri A, Evrony GD, Cai X, et al. Somatic mutation, genomic variation, and neurological disease. Science. 2013;341:1237758. [PMC free article] [PubMed]
6. Bachur CD, Comi AM. Sturge Weber syndrome. Curr Treat Options Neurol. 2013;15:607–617. [PMC free article] [PubMed]
7. Fischbein NJ, Barkovich AJ, Wu Y, et al. Sturge-Weber syndrome with no leptomeningeal enhancement on MRI. Neuroradiology. 1998;40:177–180. [PubMed]
8. Porto L, Kieslich M, Yan B, et al. Accelerated myelination associated with venous congestion. Eur Radiol. 2006;16:922–926. [PubMed]
9. Sujansky E, Conradi S. Sturge-Weber syndrome. Age of onset of seizures and glaucoma and the prognosis for affected children. J Child Neurol. 1995;10:49–58. [PubMed]
10. Kramer U, Kahana E, Shorer Z, et al. Outcome of infants with unilateral Sturge-Weber syndrome and early onset seizures. Dev Med Child Neurol. 2000;42:756–759. [PubMed]
11. Sullivan TJ, Clarke MP, Morin JD. The ocular manifestations of the Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus. 1992;19:349–356. [PubMed]
12. Ray D, Mandal AK, Chandrasekhar G, et al. Port-wine vascular malformations and glaucoma risk in Sturge-Weber syndrome. J AAPOS. 2010;14:105. [PubMed]
13. Norman MG, Schoene WC. The ultrastructure of Sturge-Weber disease. Acta Neuropathol. 1977;37:199–205. [PubMed]
14. Maton B, Krsek P, Jayakar P, et al. Medically intractable epilepsy in Sturge-Weber syndrome is associated with cortical malformation. Implications for surgical therapy. Epilepsia. 2010;51:257–267. [PubMed]
15. Kimple AJ, Bosch DE, Giguere PM, et al. Regulators of G-protein signaling and their Galpha substrates. Promises and challenges in their use as drug discovery targets. Pharmacol Rev. 2011;63:728–749. [PubMed]
16. Murakami N, Morioka T, Suzuki SO, et al. Focal cortical dysplasia type IIa underlying epileptogenesis in patients with epilepsy associated with Sturge-Weber syndrome. Epilepsia. 2012;53:e184–e188. [PubMed]
17. Smoller BR, Rosen S. Port-wine stains. A disease of altered neural modulation of blood vessels? Arch Dermatol. 1986;122:177–179. [PubMed]
18. Rydh M, Malm M, Jernbeck J, et al. Ectatic blood vessels in port-wine stains lack innervation. Possible role in pathogenesis. Plast Reconstr Surg. 1991;87:419–422. [PubMed]
19. Sa M, Barroso CP, Caldas MC, et al. Innervation pattern of malformative cortical vessels in Sturge-Weber disease. An histochemical, immunohistochemical, and ultrastructural study. Neurosurgery. 1997;41:872–876. [PubMed]
20. Rosen S, Smoller BR. Port-wine stains. A new hypothesis. J Am Acad Dermatol. 1987;17:164–166. [PubMed]
21. Ward NL, Lamanna JC. The neurovascular unit and its growth factors. Coordinated response in the vascular and nervous systems. Neurol Res. 2004;26:870–883. [PubMed]
22. Griffiths PD, Boodram MB, Blaser S, et al. 99mTechnetium HMPAO imaging in children with the Sturge-Weber syndrome. A study of nine cases with CT and MRI correlation. Neuroradiology. 1997;39:219–224. [PubMed]
23. Namer IJ, Battaglia F, Hirsch E, et al. Subtraction ictal SPECT co-registered to MRI (SISCOM) in Sturge-Weber syndrome. Clin Nucl Med. 2005;30:39–40. [PubMed]
24. Aylett SE, Neville BG, Cross JH, et al. Sturge-Weber syndrome. Cerebral haemodynamics during seizure activity. Dev Med Child Neurol. 1999;41:480–485. [PubMed]
25. Comati A, Beck H, Halliday W, et al. Upregulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha in leptomeningeal vascular malformations of Sturge-Weber syndrome. J Neuropathol Exp Neurol. 2007;66:86–97. [PubMed]
26. Sreenivasan AK, Bachur CD, Lanier KE, et al. Urine vascular biomarkers in Sturge-Weber syndrome. Vasc Med. 2013;18:122–128. [PubMed]
27. Argraves WS, Drake CJ. Genes critical to vasculogenesis as defined by systematic analysis of vascular defects in knockout mice. Anat Rec A Discov Mol Cell Evol Biol. 2005;286:875–884. [PubMed]
28. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance. Perspectives for improved drug treatment. Drug Resist Updat. 2008;11:63–76. [PMC free article] [PubMed]
29. Di Trapani G, Di Rocco C, Abbamondi AL, et al. Light microscopy and ultrastructural studies of Sturge-Weber disease. Childs Brain. 1982;9:23–36. [PubMed]
30. Chapas AM, Eickhorst K, Geronemus RG. Efficacy of early treatment of facial port wine stains in newborns. A review of 49 cases. Lasers Surg Med. 2007;39:563–568. [PubMed]
31. Iwach AG, Hoskins HD, Jr, Hetherington J, Jr, et al. Analysis of surgical and medical management of glaucoma in Sturge-Weber syndrome. Ophthalmology. 1990;97:904–909. [PubMed]
32. Patrianakos TD, Nagao K, Walton DS. Surgical management of glaucoma with the sturge weber syndrome. Int Ophthalmol Clin. 2008;48:63–78. [PubMed]
33. Kossoff EH, Ferenc L, Comi AM. An infantile-onset, severe, yet sporadic seizure pattern is common in Sturge-Weber syndrome. Epilepsia. 2009;50:2154–2157. [PubMed]
34. Fukuyama Y, Tsuchiya S. A study on Sturge-Weber syndrome. Report of a case associated with infantile spasms and electroencephalographic evolution in five cases. Eur Neurol. 1979;18:194–204. [PubMed]
35. Ewen JB, Comi AM, Kossoff EH. Myoclonic-astatic epilepsy in a child with Sturge-Weber syndrome. Pediatr Neurol. 2007;36:115–117. [PubMed]
36. Lance EI, Sreenivasan AK, Zabel TA, et al. Aspirin use in Sturge-Weber syndrome. Side effects and clinical outcomes. J Child Neurol. 2013;28:213–218. [PMC free article] [PubMed]
37. Maria BL, Neufeld JA, Rosainz LC, et al. Central nervous system structure and function in Sturge-Weber syndrome. Evidence of neurologic and radiologic progression. J Child Neurol. 1998;13:606–618. [PubMed]
38. Maria BL, Neufeld JA, Rosainz LC, et al. High prevalence of bihemispheric structural and functional defects in Sturge-Weber syndrome. J Child Neurol. 1998;13:595–605. [PubMed]
39. Udani V, Pujar S, Munot P, et al. Natural history and magnetic resonance imaging follow-up in 9 Sturge-Weber Syndrome patients and clinical correlation. J Child Neurol. 2007;22:479–483. [PubMed]
40. Bay MJ, Kossoff EH, Lehmann CU, et al. Survey of aspirin use in Sturge-Weber syndrome. J Child Neurol. 2011;26:692–702. [PubMed]
41. Lopez J, Yeom KW, Comi A, et al. Case report of subdural hematoma in a patient with Sturge-Weber syndrome and literature review. Questions and implications for therapy. J Child Neurol. 2013;28:672–675. [PubMed]
42. Greco F, Fiumara A, Sorge G, et al. Subgaleal hematoma in a child with Sturge-Weber syndrome. To prevent stroke-like episodes, is treatment with aspirin advisable? Childs Nerv Syst. 2008;24:1479–1481. [PubMed]
43. Ville D, Enjolras O, Chiron C, et al. Prophylactic antiepileptic treatment in Sturge-Weber disease. Seizure. 2002;11:145–150. [PubMed]
44. Kossoff EH, Borsage JL, Comi AM. A pilot study of the modified Atkins diet for Sturge-Weber syndrome. Epilepsy Res. 2010;92:240–243. [PubMed]
45. Kossoff EH, Buck C, Freeman J. Outcomes of 32 hemispherectomies for Sturge-Weber syndrome worldwide. Neurology. 2002;59:1735–1738. [PubMed]
46. Arzimanoglou AA, Andermann F, Aicardi J, et al. Sturge-Weber syndrome. Indications and results of surgery in 20 patients. Neurology. 2000;55:1472–1479. [PubMed]
47. Tuxhorn IE, Pannek HW. Epilepsy surgery in bilateral Sturge-Weber syndrome. Pediatr Neurol. 2002;26:394–397. [PubMed]
48. Kossoff EH, Balasta M, Hatfield LM, et al. Self-reported treatment patterns in patients with Sturge-Weber syndrome and migraines. J Child Neurol. 2007;22:720–726. [PubMed]
49. Cakirer S, Yagmurlu B, Savas MR. Sturge-Weber syndrome. Diffusion magnetic resonance imaging and proton magnetic resonance spectroscopy findings. Acta Radiol. 2005;46:407–410. [PubMed]
50. Lee JS, Asano E, Muzik O, et al. Sturge-Weber syndrome. Correlation between clinical course and FDG PET findings. Neurology. 2001;57:189–195. [PubMed]
51. Miller RS, Ball KL, Comi AM, et al. Growth hormone deficiency in Sturge-Weber syndrome. Arch Dis Child. 2006;91:340–341. [PMC free article] [PubMed]
52. Comi AM, Bellamkonda S, Ferenc LM, et al. Central hypothyroidism and Sturge-Weber syndrome. Pediatr Neurol. 2008;39:58–62. [PubMed]
53. Siddique L, Sreenivasan A, Comi AM, et al. mportance of utilizing a sensitive free thyroxine assay in Sturge-Weber syndrome. J Child Neurol. 2013;28:269–274. [PubMed]
54. Marques L, Nunez-Cordoba JM, Aguado L, et al. Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome. Phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial. J Am Acad Dermatol. 2015;72:151–158. [PubMed]